207940.KS · Korea · Healthcare · 삼성바이오로직스
As of July 13, 2026 at 08:56 PM KST, Samsung Biologics (207940.KS) has a market cap of $43B (≈ ₩64.8T) — #146 worldwide on this unified board of 300 major Korean, US, and Japanese stocks, and #9 among Korea names. Up 1 spot from yesterday's baseline.
Compared with global #1 NVIDIA Corporation ($5.11T), that is 0.8% — it would take 117.7× Samsung Biologics to match one NVIDIA Corporation. The gap to #145 Samsung Life ($44B) right above is $263M. Right below at #147 is ORIX CORPORATION ($43B).
Within the Healthcare sector it ranks #18 of 26; the sector leader is Eli Lilly and Company (global #13). The stock trades at $937.75, with roughly 46M shares outstanding (estimated).